

Nuliv Science Usa Inc.

Disclosure Report
Date Submitted: May 8th, 2025

© B Lab 2023



Disclosure Materials

Certified B Corporations must complete a Disclosure Questionnaire to identify potentially sensitive issues related to the company (e.g. historical fines, sanctions, material litigation, or sensitive industry practices).

This component does not affect the company's score on the B Impact Assessment. If the company answers affirmatively to any items in the Disclosure Questionnaire that B Lab deems relevant for public stakeholders, then, as a condition of their certification, the company must:

- Be transparent about details of the disclosure issues identified on the company's public B Impact Report
- 2) Describe how the company has addressed this issue
- 3) Demonstrate that management practices are in place to avoid similar issues from arising in the future, when necessary.

In all cases, the Standards Advisory council reserves the right to refuse certification if the company is ultimately deemed not to uphold the spirit and integrity of the community.

In addition to the voluntary indication of sensitive issues in the Disclosure Questionnaire, companies pursuing Certification also are subject to a background check by B Lab staff. Background checks include a review of public records, news sources, and search engines for company names, brands, executives/founders, and other relevant topics.

Sensitive issues identified through background checks may or may not be within the scope of questions in the Disclosure Questionnaire, but undergo the same review process and are subject to the same possible review by the Standards Advisory Council, including ineligibility for B Corp Certification, required remediation, or disclosure.

This document contains a copy of the company's completed Disclosure Questionnaire and related disclosure documentation provided by the company



Disclosure Questionnaire

Industries and Products

Yes No Please indicate if the company is involved in production of or trade in any of the following. Select Yes for all options that **Animal Products or Services** $\boxed{}$ **Biodiversity Impacts** Chemicals $\boxed{}$ **Disclosure Alcohol Disclosure Firearms Weapons** $\boxed{}$ **Disclosure Mining** $\boxed{}$ **Disclosure Pornography** $\boxed{}$ **Disclosure Tobacco** $\boxed{}$ **Energy and Emissions Intensive** $\boxed{}$ Industries Gambling \square **Genetically Modified Organisms** \square Illegal Products or Subject to \square **Phase Out** Industries at Risk of Human $\boxed{}$ **Rights Violations Monoculture Agriculture Nuclear Power or Hazardous** \square **Materials** Payday, Short Term, or High $\boxed{}$ **Interest Lending** Water Intensive Industries \square **Tax Advisory Services** \square

Outcomes & Penalties

	Yes	No
Please indicate if the company has had any formal complaint to a regulatory agency or been assessed any fine or sanction in the past five years for any of the following practices or policies. Check all that apply.		
Anti-Competitive Behavior		∀
Breaches of Confidential Information		X
Bribery, Fraud, or Corruption		V
Company has filed for bankruptcy		N.
Consumer Protection		\vee
Financial Reporting, Taxes, Investments, or Loans		N
Hazardous Discharges Into Air/Land/Water (Past 5 Yrs)		\checkmark
Labor Issues		\searrow
Large Scale Land Conversion, Acquisition, or Relocation		X
Litigation or Arbitration		\vee
On-Site Fatality		V
Penalties Assessed For Environmental Issues		V
Political Contributions or International Affairs		Y
Recalls		\checkmark
Significant Layoffs		V
Violation of Indigenous Peoples Rights		V
Other		\checkmark



Practices

	Yes	No
Please indicate if the following statements are true regarding whether or not the company engages in the following practices. Check all that apply. If the statement is true, select "Yes." If false, select "No."		
Animal Testing	V	
Company/Suppliers Employ Under Age 15 (Or Other ILO Minimum Age)		\vee
Company prohibits freedom of association/collective bargaining		\checkmark
Company workers are prisoners		\checkmark
Conduct Business in Conflict Zones		\checkmark
Confirmation of Right to Work		\checkmark
Does not transparently report corporate financials to government		\checkmark
Employs Individuals on Zero-Hour Contracts		\checkmark
Facilities located in sensitive ecosystems		\checkmark
ID Cards Withheld or Penalties for Resignation		\checkmark
No formal Registration Under Domestic Regulations		\checkmark
No signed employment contracts for all workers		∀
Overtime For Hourly Workers Is Compulsory		\vee
Payslips not provided to show wage calculation and deductions		\checkmark

	Yes	No
Sale of Data		V
Tax Reduction Through Corporate Shells		N
Workers cannot leave site during non-working hours		N
Workers not Provided Clean Drinking Water or Toilets		\triangleright
Workers paid below minimum wage		V
Workers Under Bond		\checkmark
Other		\checkmark

Supply Chain Disclosures

	Yes	No
Please indicate if any of the following statements are true regarding your company's significant suppliers.		
Business in Conflict Zones		\checkmark
Child or Forced Labor		\checkmark
Negative Environmental Impact		\checkmark
Negative Social Impact		\checkmark
Other		\checkmark



Disclosure Questionnaire Statement

Disclosure Questionnaire Category: Animal Testing

Topic	The company is legally required by the FDA to carry out animal testing on some of their products.
Summary of Issue	Nuliv Science USA Inc. is a science based ingredients company located in Brea, California. The company sells ingredients and products based on patented ingredients, including mushrooms, and botanicals. The company claims that all animal testing related to their products is legally required by the FDA in order to obtain Generally Recognised as Safe (GRAS) status. This includes individual cell testing and animal testing.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	According to the company, 3 of their 14 active ingredients underwent animal testing. They represent around 35% of the company's gross revenue and 20% of sales growth per year, on average.
Impact on Stakeholder(s)	Animal testing and experimentation is widely used to develop new products and to test the safety of other products. Many of these experiments can cause pain to the animals involved or reduce their quality of life in other ways.
Implemented Management Practices	According to the company, there are no alternatives available as the FDA explicitly demands a 90-day acute toxicity study on rats; The European Food Safety Agency requires a 90-day and, sometimes, a 180-day test depending on the existing toxicity evidence of a food compound.
	All third-party laboratories must follow Good Laboratory Practices (GLP) and follow strict protocols for animal handling as outlined by OECD guidelines.
Reports	See Nuliv Science's statement on Animal Testing: https://nulivscience.com/research/



Disclosure Questionnaire Statement

Disclosure Questionnaire Category: Environmentally Intensive Industries

Issue Date	Ongoing
Topic	Water Intensive Industries
Summary of Issue	Sanofi CHC NA does not consider itself to be a water intensive industry. Sanofi CHC NA operates in the pharmaceutical industry which has been recognised as water intensive due to their manufacturing and cleaning processes.
Size/Scope of Issue (e.g. \$ financial implication, # of individuals affected)	In the previous fiscal year, 100% of CHCNA at Sanofi's revenue was earned from the sale of over the counter medicines/drugs, food/dietary supplements and cosmetics.
	NA CHC's water intensity was calculated in 2022 as 0.30 M3 per manufacturing unit.
Impact on Stakeholder(s)	As a water intensive industry, the manufacturing of pharmaceutical products poses risks such as water stress or depletion of local water sources if water use is not appropriately managed.
	The company has a plant in Chattanooga, Tennessee which sources its water from the public water supply, not considered a water stressed area.
Implemented Management Practices	Although the company does not carry out an assessment of how it compares to others in the industry on a local level in relation to water use as there are no comparable consumer healthcare producers, benchmarks are performed on a global pharmaceutical producer level. Sanofi CHC NA does not have R&D, Bio-technology plants nor chemical plants to manufacture active pharmaceutical ingredients or excipients, nor manage biological products within its portfolio, activities generally recognized in the pharmaceutical industry as water-intensive.
	Globally Sanofi CHC has the target of reducing water consumption by 20% by 2030, with 2019 levels as a benchmark. All of Sanofi CHC's production sites will contribute to this global reduction, including the Chattanooga manufacturing facility, which is due to conduct a Gap Assessment in 2023 to establish a Water Efficiency Management Plan for NA CHC.



Sanofi CHC's sustainability strategy is based on water stewardship principles: increasing water efficiency, assessing risks in each local watershed and defining a strategy aligned with local communities to properly manage the watershed the company relies on.